Loading...
Loading...
Cardiome Pharma Corp.
CRME shares dipped 2.7% to $7.70, as the company and SteadyMed Ltd. announced that the European Medicines Agency (EMA) has approved Cardiome's request to review Trevyent® (treprostinil PatchPump) under the Centralised Authorisation Procedure drug review process. Share volume was 2,800, compared to an all-day average of 33,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in